These treatments target one or more of the proteins that stimulate growth of the leaky vessels in the eye. These treatments have been shown to improve vision by reducing the growth of new blood vessels and decreasing leakage. Eye injections are generally very well tolerated, but side effects can include bloodshot eye, blurred vision, increased pressure inside the eye and others. An eye care specialist, such as an ophthalmologist or a retina specialist, can help determine if an anti-VEGF is right for you.

This approach stabilizes vision using a laser to stop leakage into the retina and macula. Laser therapy stabilizes vision and can prevent vision loss caused by CRVO. Safety issues include possible discomfort during the procedure and potential damage or scarring to the retina.

These drugs work by targeting different mechanisms of the disease: inflammation, or swelling and VEGF factors. They can be delivered by an injection into the eye but they may cause other eye complications, such as cataracts or an increase in intraocular pressure, which is a risk factor for glaucoma.

Description: A picture of a doctor explaining something to a patient. A small side box shows a patient with eyes squinting with an arrow to another picture of the same patient looking much happier with eyes wide open.

Narration. In terms of treatment, there is no way to open or reverse the vein blockage. Some patients, with time, will have a spontaneous improvement in vision. Regardless, treatment is usually required to treat the associated problems or complications of RVO including macular edema and angiogenesis.

Description: Three boxes are drawn to show the three treatment options. The first box shows a steroid being implanted into the eye. The second box shows an eye receiving laser treatment. The third box shows an eye receiving an eye injection.

Narration: There are currently three treatment options for RVO, steroid eye implants, laser photocoagulation and anti-VEGF treatment.

Description: A picture of a cross section of an eye showing the injection of steroids from a needle-like device.

Narration: Steroids called dexamethasone implants can reduce swelling in the eyes of people with CRVO, helping to lessen or prevent more damage to the macula.

Description: Two doctors in an operating room are about to perform a steroid implant into a patient lying on the operating room table.

Narration: These implants are administered under general anesthetic, using a small injection into the back of the eye.

Description: Picture of a female doctor using a machine to point a laser into the eye of a male patient. A zoomed in section shows the laser beam hitting a small leaky blood vessel.

Narration: In laser photocoagulation, leaky blood vessels affecting central vision are sealed using a laser. This slows the leakage of fluid, reducing the amount of fluid in the retina. Laser photocoagulation can be used to treat both types of RVO but has become less common with the advent of other treatments.

Description: A three-part picture is drawn. Part one is a picture of a needle aimed at a target with the word “VEGF” in the centre of the target; part two is a picture of a main blood vessel with some small new blood vessels forming and a STOP Sign in the top corner; and part three is a picture of a doctor preparing to administer an injection into the eye of a patient.

Narration: Anti-VEGF medicine is a specialized medication for RVO that targets VEGF. It is designed to block the VEGF signals which lead to macular edema and angiogenesis. Injection of anti-VEGF medicine has been shown to restore vision in many patients with RVO. Eye injections are generally very well tolerated, but side effects can include local irritation, bleeding of the surface of the eye and, rarely, infection.

Description: A Picture of a doctor talking to a patient and showing him his appointments on a calendar.

Narration: Patients with RVO will require many regularly-scheduled appointments with possible eye injections to achieve optimal results. It is important to try not to miss any appointments.

EYLEA® blocks VEGF-A and PGF, proteins that play an important role in making the abnormal blood vessels that contribute to the progression of wAMD. EYLEA® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.).

LUCENTIS® blocks VEGF-A, a pr...

LUCENTIS® blocks VEGF-A, a protein that plays an important role in making the abnormal blood vessels that contribute to the progression of wAMD. LUCENTIS® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.). LUCENTIS® helps to stop the growth and leakage of new blood vessels in the eye, abnormal processes that contribute to the progression of wAMD.

VISUDYNE® is injected into a vein, usually in the arm, and travels to the abnormal blood vessels in the e...

VISUDYNE® is injected into a vein, usually in the arm, and travels to the abnormal blood vessels in the eye. After a few minutes, the doctor shines a non-thermal laser on the affected area of the eye to activate VISUDYNE®. This starts a chemical process that destroys the abnormal vessels growing in the macula and has been shown to slow vision loss from wAMD, slow or stop the growth of the areas containing the abnormal blood vessels and reduce or stop their leakage.

Once a month for the first three months then once every two months for the first twelve months of treatment.
After the first 12 months of treatment, EYLEA® may be administered up to once every three months based on your doctor's assessment.

Once a month for the first three months. Aft...

Once a month for the first three months. Afterwards, your doctor will continue to monitor your vision and the frequency of dosing can be between one and three months:
LUCENTIS® given every 3 months was not as effective as when given once a month in clinical trials.

Your doctor will calculate the correct dose to give you, based on your body surface area.

Your doctor will calculate the correct dose to give you, based on your body surface area.

Very common side effects:Bloodshot eye.
Common side effects:Decreased sharpness of vision, clouding of the lens, damage to the front layer of the eye, increase in eye pressure, blurred vision, moving spots in vision, detachment of the gel like substance inside the eye (vitreous) from the retina, a feeling of having something in the eye, increased tear production, swelling of the eyelid, eye pain, pain or bleeding at the injection site, redness of the eye and swelling of the front layer of the eyeball.
Serious side effects:
In clinical studies, serious side effects such as infection or inflammation inside the eye, sudden loss or change of sharpness of vision (detachment or tear of retina), increase of pressure inside the eye, clouding of the lens (cataract) and detachment of the gel-like substance inside the eye from the retina (vitreous detachment) occurred in less than 1 in every 1,000 injections.

Very common side effects in the eye:...

Very common side effects in the eye:Bloodshot eye, eye pain, small particles or spots in your vision, increased pressure inside the eye, displacement of the jelly-like portion inside the eye (vitreous body), swelling of the eye, blurred vision, eye irritation, clouding of the lens, a feeling of having something in the eye, visual disturbance, swelling or infection of the eyelid margin, formation of fibrous tissue under the retina, redness of the eye, blurred or decreased sharpness of vision, dry eye, inflammation of the jelly-like portion inside the eye, temporary blindness, increased tear production, itching of the eye, detachment of a layer of the retina.
Common side effects in the eye:Discomfort of the eye, clouding of a part of the lens, deposits in the back of the eye, infection of the surface of the eye, changes in the part of the retina responsible for central vision, bleeding in the back of the eye, degeneration of the retina, small scratches on the cornea (front part of the eye), bleeding in the eye or at the site of injection, tear or detachment of the retina, redness of the eye, light sensitivity, swelling of the eyelid, eyelid pain, eye discharge and bleeding in the jelly-like portion inside the eye.
Serious side effects:
Occasionally an infection in the internal portion of the eye, detachment or tear of the retina, or clouding of the lens may occur in the two weeks after LUCENTIS® treatment. Other side effects include pain or redness and increased eye pressure.

Common side effects:Changes in vision including blurring, decreased sharpness, flashes of light and gaps or 'spider webs' in vision were amo...

Common side effects:Changes in vision including blurring, decreased sharpness, flashes of light and gaps or 'spider webs' in vision were among the most frequent+ly reported side effects. Temporary musculoskeletal pain occurring often as chest and back pain which can radiate to other areas including the pelvis, shoulder girdle or ribs. Weakness, nausea, constipation, hypertension, elevated blood cholesterol or urinary glucose, dry, itchy or painful eyes, aversion to light, decrease in pain or touch sensitivity, sunburn or increased sensitivity to the sun and injection site reactions (e.g., pain, swelling, blisters and discolouration).
Serious side effects:
Severe vision decrease, changes in the visual field, hypersensitivity (allergic reactions) and injection site reactions.

Anti-VEGF treatment-EYLEA®Toggle show/hide. Screen reader users, all text is available without show hide.

EYLEA® blocks VEGF-A and PGF, proteins that play an important role in making the abnormal blood vessels that contribute to the progression of wAMD. EYLEA® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.).

Once a month for the first three months then once every two months for the first twelve months of treatment.
After the first 12 months of treatment, EYLEA® may be administered up to once every three months based on your doctor's assessment.

Very common side effects:Bloodshot eye.
Common side effects:Decreased sharpness of vision, clouding of the lens, damage to the front layer of the eye, increase in eye pressure, blurred vision, moving spots in vision, detachment of the gel like substance inside the eye (vitreous) from the retina, a feeling of having something in the eye, increased tear production, swelling of the eyelid, eye pain, pain or bleeding at the injection site, redness of the eye and swelling of the front layer of the eyeball.
Serious side effects:
In clinical studies, serious side effects such as infection or inflammation inside the eye, sudden loss or change of sharpness of vision (detachment or tear of retina), increase of pressure inside the eye, clouding of the lens (cataract) and detachment of the gel-like substance inside the eye from the retina (vitreous detachment) occurred in less than 1 in every 1,000 injections.

Anti-VEGF treatment-LUCENTIS®Toggle show/hide. Screen reader users, all text is available without show hide.

LUCENTIS® blocks VEGF-A, a protein that plays an important role in making the abnormal blood vessels that contribute to the progression of wAMD. LUCENTIS® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.). LUCENTIS® helps to stop the growth and leakage of new blood vessels in the eye, abnormal processes that contribute to the progression of wAMD.

Once a month for the first three months. Afterwards, your doctor will continue to monitor your vision and the frequency of dosing can be between one and three months:
LUCENTIS® given every 3 months was not as effective as when given once a month in clinical trials.

Very common side effects in the eye:Bloodshot eye, eye pain, small particles or spots in your vision, increased pressure inside the eye, displacement of the jelly-like portion inside the eye (vitreous body), swelling of the eye, blurred vision, eye irritation, clouding of the lens, a feeling of having something in the eye, visual disturbance, swelling or infection of the eyelid margin, formation of fibrous tissue under the retina, redness of the eye, blurred or decreased sharpness of vision, dry eye, inflammation of the jelly-like portion inside the eye, temporary blindness, increased tear production, itching of the eye, detachment of a layer of the retina.
Common side effects in the eye:Discomfort of the eye, clouding of a part of the lens, deposits in the back of the eye, infection of the surface of the eye, changes in the part of the retina responsible for central vision, bleeding in the back of the eye, degeneration of the retina, small scratches on the cornea (front part of the eye), bleeding in the eye or at the site of injection, tear or detachment of the retina, redness of the eye, light sensitivity, swelling of the eyelid, eyelid pain, eye discharge and bleeding in the jelly-like portion inside the eye.
Serious side effects:
Occasionally an infection in the internal portion of the eye, detachment or tear of the retina, or clouding of the lens may occur in the two weeks after LUCENTIS® treatment. Other side effects include pain or redness and increased eye pressure.

Photodynamic therapy (PDT) VISUDYNE®Toggle show/hide. Screen reader users, all text is available without show hide.

VISUDYNE® is injected into a vein, usually in the arm, and travels to the abnormal blood vessels in the eye. After a few minutes, the doctor shines a non-thermal laser on the affected area of the eye to activate VISUDYNE®. This starts a chemical process that destroys the abnormal vessels growing in the macula and has been shown to slow vision loss from wAMD, slow or stop the growth of the areas containing the abnormal blood vessels and reduce or stop their leakage.

Common side effects:Changes in vision including blurring, decreased sharpness, flashes of light and gaps or 'spider webs' in vision were among the most frequent+ly reported side effects. Temporary musculoskeletal pain occurring often as chest and back pain which can radiate to other areas including the pelvis, shoulder girdle or ribs. Weakness, nausea, constipation, hypertension, elevated blood cholesterol or urinary glucose, dry, itchy or painful eyes, aversion to light, decrease in pain or touch sensitivity, sunburn or increased sensitivity to the sun and injection site reactions (e.g., pain, swelling, blisters and discolouration).
Serious side effects:
Severe vision decrease, changes in the visual field, hypersensitivity (allergic reactions) and injection site reactions.

EYLEA® blocks VEGF-A and PGF, proteins that play an important role in making the abnormal blood vessels that contribute to the macular edema (swelling) that is seen with DME. EYLEA® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.).

LUCENTIS® blocks VEGF-A, a pr...

LUCENTIS® blocks VEGF-A, a protein that plays an important role in making the abnormal blood vessels that contribute to the progression of DME. LUCENTIS® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.). LUCENTIS® helps to stop the growth and leakage of new blood vessels in the eye, abnormal processes that contribute to the development of macular edema (swelling) due to DME.

A laser is used to create small burns in areas of the retina where abnormal blood vessels have formed to try to seal the...

A laser is used to create small burns in areas of the retina where abnormal blood vessels have formed to try to seal the leaks.

By reducing swelling of the macula, the ster...

By reducing swelling of the macula, the steroid helps to lessen or prevent more damage to the macula. It also reduces the inflammation of the back of the eye.

Once a month for the first five months then you may be given injections once every two months. Your doctor may decide to treat you with EYLEA® as frequently as every month.

Once a month. If your vision remains the sam...

Once a month. If your vision remains the same while you are being given LUCENTIS® treatment, your doctor may decide to stop the treatment with LUCENTIS®. Your doctor will continue to monitor your vision monthly and will decide if treatment with LUCENTIS® should be resumed or not. Your doctor may decide that you also need to be treated with laser; if so, laser treatment can be administered together with LUCENTIS®.

The procedure is usually completed in one session but further treatment may be needed. If you require laser treatment to...

The procedure is usually completed in one session but further treatment may be needed. If you require laser treatment to both eyes, they will be treated one at a time, usually several weeks apart.

The usual dose is one implant to be given by...

The usual dose is one implant to be given by injection into your eye. Six months after the injection and depending on the effect of OZURDEX®, your doctor may or may not want to give you a subsequent OZURDEX® injection.

Very common side effects:Bloodshot eye.
Common side effects:Decreased sharpness of vision, clouding of the lens, damage to the front layer of the eye, increase in eye pressure, blurred vision, moving spots in vision, detachment of the gel like substance inside the eye (vitreous) from the retina, a feeling of having something in the eye, increased tear production, swelling of the eyelid, eye pain, pain or bleeding at the injection site, redness of the eye and swelling of the front layer of the eyeball.
Serious side effects:
In clinical studies, serious side effects due to the injection procedure, including retinal detachment, occurred in 1 out of 5,940 injections.

Very common side effects in the eye:...

Very common side effects in the eye:Bloodshot eye, eye pain, small particles or spots in your vision, increased pressure inside the eye, displacement of the jelly-like portion inside the eye (vitreous body), swelling of the eye, blurred vision, eye irritation, clouding of the lens, a feeling of having something in the eye, visual disturbance, swelling or infection of the eyelid margin, formation of fibrous tissue under the retina, redness of the eye, blurred or decreased sharpness of vision, dry eye, inflammation of the jelly-like portion inside the eye, temporary blindness, increased tear production, itching of the eye, detachment of a layer of the retina.
Common side effects in the eye:Discomfort of the eye, clouding of a part of the lens, deposits in the back of the eye, infection of the surface of the eye, changes in the part of the retina responsible for central vision, bleeding in the back of the eye, degeneration of the retina, small scratches on the cornea (front part of the eye), bleeding in the eye or at the site of injection, tear or detachment of the retina, redness of the eye, light sensitivity, swelling of the eyelid, eyelid pain, eye discharge and bleeding in the jelly-like portion inside the eye.
Serious side effects:
Occasionally an infection in the internal portion of the eye, detachment or tear of the retina, or clouding of the lens may occur in the two weeks after LUCENTIS® treatment. Other side effects include pain or redness and increased eye pressure.

With this procedure, some side vision may be lost in order to safeguard central vision and scarring of the macula and ad...

With this procedure, some side vision may be lost in order to safeguard central vision and scarring of the macula and additional vision loss may occur.

Very common side effects:Increased pressure in the eye,...

Very common side effects:Increased pressure in the eye, clouding of the lens (cataract) and bleeding on the surface of the eye.*
Common side effects:High pressure in the eye, bleeding into the inside of the eye*, vitreous detachment, a feeling of spots in front of the eye (including 'floaters')*, a feeling of looking through mist or fog*, eye pain and swelling on the surface of the eye*.*Some of these side effects may be caused by the injection procedure and not the OZURDEX® implant itself.

Anti-VEGF treatment-EYLEA®Toggle show/hide. Screen reader users, all text is available without show hide.

EYLEA® blocks VEGF-A and PGF, proteins that play an important role in making the abnormal blood vessels that contribute to the macular edema (swelling) that is seen with DME. EYLEA® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.).

Very common side effects:Bloodshot eye.
Common side effects:Decreased sharpness of vision, clouding of the lens, damage to the front layer of the eye, increase in eye pressure, blurred vision, moving spots in vision, detachment of the gel like substance inside the eye (vitreous) from the retina, a feeling of having something in the eye, increased tear production, swelling of the eyelid, eye pain, pain or bleeding at the injection site, redness of the eye and swelling of the front layer of the eyeball.
Serious side effects:
In clinical studies, serious side effects due to the injection procedure, including retinal detachment, occurred in 1 out of 5,940 injections.

Anti-VEGF treatment-LUCENTIS®Toggle show/hide. Screen reader users, all text is available without show hide.

LUCENTIS® blocks VEGF-A, a protein that plays an important role in making the abnormal blood vessels that contribute to the progression of DME. LUCENTIS® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.). LUCENTIS® helps to stop the growth and leakage of new blood vessels in the eye, abnormal processes that contribute to the development of macular edema (swelling) due to DME.

Once a month. If your vision remains the same while you are being given LUCENTIS® treatment, your doctor may decide to stop the treatment with LUCENTIS®. Your doctor will continue to monitor your vision monthly and will decide if treatment with LUCENTIS® should be resumed or not. Your doctor may decide that you also need to be treated with laser; if so, laser treatment can be administered together with LUCENTIS®.

Very common side effects in the eye:Bloodshot eye, eye pain, small particles or spots in your vision, increased pressure inside the eye, displacement of the jelly-like portion inside the eye (vitreous body), swelling of the eye, blurred vision, eye irritation, clouding of the lens, a feeling of having something in the eye, visual disturbance, swelling or infection of the eyelid margin, formation of fibrous tissue under the retina, redness of the eye, blurred or decreased sharpness of vision, dry eye, inflammation of the jelly-like portion inside the eye, temporary blindness, increased tear production, itching of the eye, detachment of a layer of the retina.
Common side effects in the eye:Discomfort of the eye, clouding of a part of the lens, deposits in the back of the eye, infection of the surface of the eye, changes in the part of the retina responsible for central vision, bleeding in the back of the eye, degeneration of the retina, small scratches on the cornea (front part of the eye), bleeding in the eye or at the site of injection, tear or detachment of the retina, redness of the eye, light sensitivity, swelling of the eyelid, eyelid pain, eye discharge and bleeding in the jelly-like portion inside the eye.
Serious side effects:
Occasionally an infection in the internal portion of the eye, detachment or tear of the retina, or clouding of the lens may occur in the two weeks after LUCENTIS® treatment. Other side effects include pain or redness and increased eye pressure.

Laser photocoagulationToggle show/hide. Screen reader users, all text is available without show hide.

The usual dose is one implant to be given by injection into your eye. Six months after the injection and depending on the effect of OZURDEX®, your doctor may or may not want to give you a subsequent OZURDEX® injection.

Very common side effects:Increased pressure in the eye, clouding of the lens (cataract) and bleeding on the surface of the eye.*
Common side effects:High pressure in the eye, bleeding into the inside of the eye*, vitreous detachment, a feeling of spots in front of the eye (including 'floaters')*, a feeling of looking through mist or fog*, eye pain and swelling on the surface of the eye*.*Some of these side effects may be caused by the injection procedure and not the OZURDEX® implant itself.

EYLEA® blocks VEGF-A and PGF, proteins that play an important role in making the abnormal blood vessels that contribute to the progression of CRVO. EYLEA® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.).

LUCENTIS® blocks VEGF-A, a pr...

LUCENTIS® blocks VEGF-A, a protein that plays an important role in making the abnormal blood vessels that contribute to the progression of CRVO. LUCENTIS® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.). LUCENTIS® helps to stop the growth and leakage of new blood vessels in the eye, abnormal processes that contribute to the progression of RVO.

A laser is used to create small burns in areas of the retina where abnormal blood vessels have formed to try to seal the...

A laser is used to create small burns in areas of the retina where abnormal blood vessels have formed to try to seal the leaks.

By reducing swelling of the macula, the ster...

By reducing swelling of the macula, the steroid helps to lessen or prevent more damage to the macula. It also reduces the inflammation of the back of the eye.

From once a month to once every three months based on examination by a doctor.

Once a month. If your vision remains the sam...

Once a month. If your vision remains the same while you are being given LUCENTIS® treatment, your doctor may decide to stop the treatment with LUCENTIS®. Your doctor will continue to monitor your vision monthly and will decide if treatment with LUCENTIS® should be resumed or not. Your doctor may decide that you also need to be treated with laser; if so, laser treatment can be administered together with LUCENTIS®.

The procedure is usually completed in one session but further treatment may be needed. If you require laser treatment to...

The procedure is usually completed in one session but further treatment may be needed. If you require laser treatment to both eyes, they will be treated one at a time, usually several weeks apart.

The usual dose is one implant to be given by...

The usual dose is one implant to be given by injection into your eye. Six months after the injection and depending on the effect of OZURDEX®, your doctor may or may not want to give you a subsequent OZURDEX® injection.

Very common side effects:Bloodshot eye.
Common side effects:Decreased sharpness of vision, clouding of the lens, damage to the front layer of the eye, increase in eye pressure, blurred vision, moving spots in vision, detachment of the gel like substance inside the eye (vitreous) from the retina, a feeling of having something in the eye, increased tear production, swelling of the eyelid, eye pain, pain or bleeding at the injection site, redness of the eye and swelling of the front layer of the eyeball.
Serious side effects:
In clinical studies, serious side effects due to the injection procedure, including endophthalmitis, cataract and vitreous detachment, occurred in 3 out of 2,728 injections.

Very common side effects in the eye:...

Very common side effects in the eye:Bloodshot eye, eye pain, small particles or spots in your vision, increased pressure inside the eye, displacement of the jelly-like portion inside the eye (vitreous body), swelling of the eye, blurred vision, eye irritation, clouding of the lens, a feeling of having something in the eye, visual disturbance, swelling or infection of the eyelid margin, formation of fibrous tissue under the retina, redness of the eye, blurred or decreased sharpness of vision, dry eye, inflammation of the jelly-like portion inside the eye, temporary blindness, increased tear production, itching of the eye, detachment of a layer of the retina.
Common side effects in the eye:Discomfort of the eye, clouding of a part of the lens, deposits in the back of the eye, infection of the surface of the eye, changes in the part of the retina responsible for central vision, bleeding in the back of the eye, degeneration of the retina, small scratches on the cornea (front part of the eye), bleeding in the eye or at the site of injection, tear or detachment of the retina, redness of the eye, light sensitivity, swelling of the eyelid, eyelid pain, eye discharge and bleeding in the jelly-like portion inside the eye.
Serious side effects:
Occasionally an infection in the internal portion of the eye, detachment or tear of the retina, or clouding of the lens may occur in the two weeks after LUCENTIS® treatment. Other side effects include pain or redness and increased eye pressure.

With this procedure, some side vision may be lost in order to safeguard central vision and scarring of the macula and ad...

With this procedure, some side vision may be lost in order to safeguard central vision and scarring of the macula and additional vision loss may occur.

Very common side effects:Increased pressure in the eye,...

Very common side effects:Increased pressure in the eye, clouding of the lens (cataract) and bleeding on the surface of the eye.*
Common side effects:High pressure in the eye, bleeding into the inside of the eye*, vitreous detachment, a feeling of spots in front of the eye (including 'floaters')*, a feeling of looking through mist or fog*, eye pain and swelling on the surface of the eye*.*Some of these side effects may be caused by the injection procedure and not the OZURDEX® implant itself.

Anti-VEGF treatment-EYLEA®Toggle show/hide. Screen reader users, all text is available without show hide.

EYLEA® blocks VEGF-A and PGF, proteins that play an important role in making the abnormal blood vessels that contribute to the progression of CRVO. EYLEA® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.).

Very common side effects:Bloodshot eye.
Common side effects:Decreased sharpness of vision, clouding of the lens, damage to the front layer of the eye, increase in eye pressure, blurred vision, moving spots in vision, detachment of the gel like substance inside the eye (vitreous) from the retina, a feeling of having something in the eye, increased tear production, swelling of the eyelid, eye pain, pain or bleeding at the injection site, redness of the eye and swelling of the front layer of the eyeball.
Serious side effects:
In clinical studies, serious side effects due to the injection procedure, including endophthalmitis, cataract and vitreous detachment, occurred in 3 out of 2,728 injections.

Anti-VEGF treatment-LUCENTIS®Toggle show/hide. Screen reader users, all text is available without show hide.

LUCENTIS® blocks VEGF-A, a protein that plays an important role in making the abnormal blood vessels that contribute to the progression of CRVO. LUCENTIS® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.). LUCENTIS® helps to stop the growth and leakage of new blood vessels in the eye, abnormal processes that contribute to the progression of RVO.

Once a month. If your vision remains the same while you are being given LUCENTIS® treatment, your doctor may decide to stop the treatment with LUCENTIS®. Your doctor will continue to monitor your vision monthly and will decide if treatment with LUCENTIS® should be resumed or not. Your doctor may decide that you also need to be treated with laser; if so, laser treatment can be administered together with LUCENTIS®.

Very common side effects in the eye:Bloodshot eye, eye pain, small particles or spots in your vision, increased pressure inside the eye, displacement of the jelly-like portion inside the eye (vitreous body), swelling of the eye, blurred vision, eye irritation, clouding of the lens, a feeling of having something in the eye, visual disturbance, swelling or infection of the eyelid margin, formation of fibrous tissue under the retina, redness of the eye, blurred or decreased sharpness of vision, dry eye, inflammation of the jelly-like portion inside the eye, temporary blindness, increased tear production, itching of the eye, detachment of a layer of the retina.
Common side effects in the eye:Discomfort of the eye, clouding of a part of the lens, deposits in the back of the eye, infection of the surface of the eye, changes in the part of the retina responsible for central vision, bleeding in the back of the eye, degeneration of the retina, small scratches on the cornea (front part of the eye), bleeding in the eye or at the site of injection, tear or detachment of the retina, redness of the eye, light sensitivity, swelling of the eyelid, eyelid pain, eye discharge and bleeding in the jelly-like portion inside the eye.
Serious side effects:
Occasionally an infection in the internal portion of the eye, detachment or tear of the retina, or clouding of the lens may occur in the two weeks after LUCENTIS® treatment. Other side effects include pain or redness and increased eye pressure.

Laser photocoagulationToggle show/hide. Screen reader users, all text is available without show hide.

The usual dose is one implant to be given by injection into your eye. Six months after the injection and depending on the effect of OZURDEX®, your doctor may or may not want to give you a subsequent OZURDEX® injection.

Very common side effects:Increased pressure in the eye, clouding of the lens (cataract) and bleeding on the surface of the eye.*
Common side effects:High pressure in the eye, bleeding into the inside of the eye*, vitreous detachment, a feeling of spots in front of the eye (including 'floaters')*, a feeling of looking through mist or fog*, eye pain and swelling on the surface of the eye*.*Some of these side effects may be caused by the injection procedure and not the OZURDEX® implant itself.

EYLEA® blocks VEGF-A and PGF, proteins that play an important role in making the abnormal blood vessels that contribute to the progression of BRVO. EYLEA® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.).

LUCENTIS® blocks VEGF-A, a pr...

LUCENTIS® blocks VEGF-A, a protein that plays an important role in making the abnormal blood vessels that contribute to the progression of BRVO. LUCENTIS® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.). LUCENTIS® helps to stop the growth and leakage of new blood vessels in the eye, abnormal processes that contribute to the progression of RVO.

A laser is used to create small burns in areas of the retina where abnormal blood vessels have formed to try to seal the...

A laser is used to create small burns in areas of the retina where abnormal blood vessels have formed to try to seal the leaks.

From once a month to once every three months based on examination by a doctor.

Once a month. If your vision remains the sam...

Once a month. If your vision remains the same while you are being given LUCENTIS® treatment, your doctor may decide to stop the treatment with LUCENTIS®. Your doctor will continue to monitor your vision monthly and will decide if treatment with LUCENTIS® should be resumed or not. Your doctor may decide that you also need to be treated with laser; if so, laser treatment can be administered together with LUCENTIS®.

The procedure is usually completed in one session but further treatment may be needed. If you require laser treatment to...

The procedure is usually completed in one session but further treatment may be needed. If you require laser treatment to both eyes, they will be treated one at a time, usually several weeks apart.

Very common side effects:Bloodshot eye.
Common side effects: Decreased sharpness of vision, clouding of the lens, damage to the front layer of the eye, increase in eye pressure, blurred vision, moving spots in vision, detachment of the gel like substance inside the eye (vitreous) from the retina, a feeling of having something in the eye, increased tear production, swelling of the eyelid, eye pain, pain or bleeding at the injection site, redness of the eye and swelling of the front layer of the eyeball.
Serious side effects:
In clinical studies, serious side effects due to the injection procedure, including cataract, occurred in 1 out of 1,115 injections.

Very common side effects in the eye:...

Very common side effects in the eye:Bloodshot eye, eye pain, small particles or spots in your vision, increased pressure inside the eye, displacement of the jelly-like portion inside the eye (vitreous body), swelling of the eye, blurred vision, eye irritation, clouding of the lens, a feeling of having something in the eye, visual disturbance, swelling or infection of the eyelid margin, formation of fibrous tissue under the retina, redness of the eye, blurred or decreased sharpness of vision, dry eye, inflammation of the jelly-like portion inside the eye, temporary blindness, increased tear production, itching of the eye, detachment of a layer of the retina.
Common side effects in the eye:Discomfort of the eye, clouding of a part of the lens, deposits in the back of the eye, infection of the surface of the eye, changes in the part of the retina responsible for central vision, bleeding in the back of the eye, degeneration of the retina, small scratches on the cornea (front part of the eye), bleeding in the eye or at the site of injection, tear or detachment of the retina, redness of the eye, light sensitivity, swelling of the eyelid, eyelid pain, eye discharge and bleeding in the jelly-like portion inside the eye.
Serious side effects:
Occasionally an infection in the internal portion of the eye, detachment or tear of the retina, or clouding of the lens may occur in the two weeks after LUCENTIS® treatment. Other side effects include pain or redness and increased eye pressure.

With this procedure, some side vision may be lost in order to safeguard central vision and scarring of the macula and ad...

With this procedure, some side vision may be lost in order to safeguard central vision and scarring of the macula and additional vision loss may occur.

Anti-VEGF treatment-EYLEA®Toggle show/hide. Screen reader users, all text is available without show hide.

EYLEA® blocks VEGF-A and PGF, proteins that play an important role in making the abnormal blood vessels that contribute to the progression of BRVO. EYLEA® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.).

Very common side effects:Bloodshot eye.
Common side effects: Decreased sharpness of vision, clouding of the lens, damage to the front layer of the eye, increase in eye pressure, blurred vision, moving spots in vision, detachment of the gel like substance inside the eye (vitreous) from the retina, a feeling of having something in the eye, increased tear production, swelling of the eyelid, eye pain, pain or bleeding at the injection site, redness of the eye and swelling of the front layer of the eyeball.
Serious side effects:
In clinical studies, serious side effects due to the injection procedure, including cataract, occurred in 1 out of 1,115 injections.

Anti-VEGF treatment-LUCENTIS®Toggle show/hide. Screen reader users, all text is available without show hide.

LUCENTIS® blocks VEGF-A, a protein that plays an important role in making the abnormal blood vessels that contribute to the progression of BRVO. LUCENTIS® has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g., reading, driving, etc.). LUCENTIS® helps to stop the growth and leakage of new blood vessels in the eye, abnormal processes that contribute to the progression of RVO.

Once a month. If your vision remains the same while you are being given LUCENTIS® treatment, your doctor may decide to stop the treatment with LUCENTIS®. Your doctor will continue to monitor your vision monthly and will decide if treatment with LUCENTIS® should be resumed or not. Your doctor may decide that you also need to be treated with laser; if so, laser treatment can be administered together with LUCENTIS®.

Very common side effects in the eye:Bloodshot eye, eye pain, small particles or spots in your vision, increased pressure inside the eye, displacement of the jelly-like portion inside the eye (vitreous body), swelling of the eye, blurred vision, eye irritation, clouding of the lens, a feeling of having something in the eye, visual disturbance, swelling or infection of the eyelid margin, formation of fibrous tissue under the retina, redness of the eye, blurred or decreased sharpness of vision, dry eye, inflammation of the jelly-like portion inside the eye, temporary blindness, increased tear production, itching of the eye, detachment of a layer of the retina.
Common side effects in the eye:Discomfort of the eye, clouding of a part of the lens, deposits in the back of the eye, infection of the surface of the eye, changes in the part of the retina responsible for central vision, bleeding in the back of the eye, degeneration of the retina, small scratches on the cornea (front part of the eye), bleeding in the eye or at the site of injection, tear or detachment of the retina, redness of the eye, light sensitivity, swelling of the eyelid, eyelid pain, eye discharge and bleeding in the jelly-like portion inside the eye.
Serious side effects:
Occasionally an infection in the internal portion of the eye, detachment or tear of the retina, or clouding of the lens may occur in the two weeks after LUCENTIS® treatment. Other side effects include pain or redness and increased eye pressure.

Laser photocoagulationToggle show/hide. Screen reader users, all text is available without show hide.

The information provided in this Web site is intended solely as general information for educational purposes only. It is not intended to replace the advice and care of your doctor, nor is it intended to be used for medical diagnosis or treatment. Should you have any questions regarding your treatment or condition, always consult your doctor or another health care professional.

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following ways: